e-Drug3D

1793

FLIBANSERIN

INN
FLIBANSERIN

cas 167933-07-5

CLASS

NERVOUS SYSTEM
TREATMENT OF PREMENOPAUSAL WOMEN WITH ACQUIRED GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
SEROTONIN RECEPTORS
5-HT1A AGONIST
5-HT2A ANTAGONIST
DOPAMINE D4, 5-HT2B AND 5-HT2C (ANTAGONIST WITH MODERATE AFFINITY)

ROUTE (list)

ORAL

ATC code

G02CX02

PK parameters

F 33 PERCENT
Tmax .075 HOUR
PPB 98 PERCENT
t1/2 11 HOUR

Solubility

INSOLUBLE IN WATER

Target

TARGET 5-HT1A RECEPTOR
5-HT2A RECEPTOR

DrugCentral

5-hydroxytryptamine receptor 1A UNIPROT P08908 HTR1A

5-hydroxytryptamine receptor 2A UNIPROT P28223 HTR2A

Download SDF file

2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-

Formula:
C20H21F3N4O

Calculated chemical properties:

MW 390.41
NB_atoms 28
XLogP 3.17
PSA 45.373
NB_HD 1
NB_HA 5
fsp3 0.35
Lipinski(0=no;1=yes) 1

FDA
NDA 022526 (label) INN (FLIBANSERIN) ADDYI (SPROUT PHARMS) APPROVAL= AP YEAR= 2015 NEWMOLECULARENTITY